DCV/ASV/BMS-791325

DRUG4 trials

Sponsors

Bristol-Myers Squibb, Timothy Morgan, MD

Conditions

Hepatitis CHepatitis C Virus

Phase 2

Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)

CompletedNCT02175966

Bristol-Myers SquibbHepatitis C

Start: 2014-07-28End: 2015-12-17Updated: 2020-08-11

Phase 3

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

CompletedNCT01979939

Bristol-Myers SquibbHepatitis C

Start: 2013-12-31End: 2014-11-30Updated: 2015-11-03

A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1

CompletedNCT02170727

Bristol-Myers SquibbHepatitis C Virus

Start: 2014-06-26End: 2015-09-09Updated: 2020-10-29

Unknown Phase

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus

CompletedNCT02098616

Timothy Morgan, MDHepatitis C

Start: 2014-07-31End: 2016-02-29Updated: 2016-04-19

Related Papers

Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1.

2017-12-0111 citations

Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study).

2017-02-0230 citations

Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection

JAMA2015-05-0594 citations

Sustained Virologic Response of 91% in Patients Infected with HCV Treated with DCV-TRIO

MD Conference Express2014-12-01